相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- CU Anschutz rheumatologists Liudmila Kastsianok, MD, and Steven Taylor, MD, have expanded rheumatology services to off-campus UCHealth clinics in Lone Tree and Cherry Creek to reach underserved patients. - The team is developing inpatient and outpatient eConsults that let rheumatologists advise referring primary care providers without a face-to-face visit, cutting response time to under 48 hours versus a roughly 30-day average wait. - The UCHealth Rheumatology Clinic's access metric grew by 9.4% year over year, and median lag time to see a rheumatologist decreased by 19 days. - The initiative addresses a worsening rheumatologist shortage amid autoimmune disease diagnoses rising roughly 3% to 12% annually.
- The Clinical Research Recruitment Program at CU Anschutz redesigned its research studies website, leading to a doubling of submissions through "Get Started Now" forms. - Nationally, about one-third of clinical trials fail to meet recruitment goals, causing costly timeline extensions and delayed discoveries. - The program, launched in late 2023 under the CCTSI grant, supports investigators across CU Anschutz, UCHealth, and Children's Hospital Colorado. - The website redesign project earned first place in the CU Innovation & Efficiency Awards for its data-driven approach to improving user experience.
- Bayer has established its first strategic alliance with an academic medical center, partnering with the University of Colorado Anschutz, UCHealth, and Children's Hospital Colorado to accelerate clinical research. - The alliance targets seven therapeutic areas including oncology, cardiovascular disease, chronic kidney disease, neurodegenerative disease, cell and gene therapy, women's health, and ophthalmology. - A Phase III trial for an investigational cellular therapy for advanced Parkinson's disease at UCHealth University of Colorado Hospital is among the first initiatives under the collaboration. - The partnership aims to expand clinical trial infrastructure, speed trial launch times through enhanced data science capabilities, and broaden patient access to investigational therapies.
- A structured pre-radiation dental clearance program at CU Anschutz, led by Dr. Petros Yoon and Dr. Ryan Lanning, integrates dentistry directly into oncology care to reduce serious complications like osteoradionecrosis. - The collaborative model features clear referral guidelines, a dedicated clinic session, and standardized clearance forms that support both academic and community dentists in managing cancer patients. - Dental clearance principles extend beyond head and neck cancer to bone marrow transplant, solid organ transplant, and certain cardiac procedures, highlighting the broader role of oral health in medically complex patients. - Long-term preventive strategies, including prescription fluoride use and regular monitoring, are emphasized to manage radiation-induced changes such as xerostomia and increased caries risk.
- Verily Health Inc. raised $300 million in Series X Capital-led funding, with Alphabet relinquishing its controlling stake while remaining a significant minority investor. - The company restructured from an LLC to an independent corporation, gaining neutrality needed for healthcare industry partnerships and data sharing collaborations. - Verily's AI-native precision health platform includes the Pre platform for clinical research acceleration and Lightpath for chronic disease management. - Strategic partnerships with Samsung Galaxy Watch, Salesforce Agentforce Health, and UCHealth demonstrate commercial momentum in biomarker development and enterprise health solutions.
- The University of Colorado Anschutz Medical Campus received a $29 million grant from Octapharma to lead the EFFECT Trial, evaluating early fibrinogen replacement in trauma patients with life-threatening bleeding. - The multicenter randomized trial will enroll 800 participants across 12 top-tier trauma centers, representing the first U.S. clinical trial to rigorously evaluate fibrinogen concentrate as a frontline trauma intervention. - The study aims to address hemorrhage, the primary cause of preventable death after traumatic injury, by targeting fibrinogen depletion which occurs first among coagulation factors. - Results could transform trauma resuscitation protocols for both civilian and military care, potentially influencing global trauma treatment guidelines.
- Flatiron Health and University of Colorado Cancer Center launch collaboration to implement Clinical Pipe™, an advanced EHR-to-EDC connector that streamlines clinical trial data capture. - The technology demonstrates remarkable efficiency, enabling transfer of over 11,000 data points with average submission times of just 37 seconds, significantly reducing administrative burden. - This partnership aims to expand clinical trial access and accelerate cancer research by automating data entry processes across UCHealth's network of care facilities.
